IN8bio (NasdaqGM:INAB) FY Conference Transcript

Summary of IN8bio FY Conference Call (March 02, 2026) Company Overview - Company: IN8bio (NasdaqGM:INAB) - Focus: Development of gamma delta T cells as therapeutics for oncology and autoimmune diseases - Expertise: The company claims to be among the world's best in gamma delta T cell therapeutics, with a scientific co-founder having over 30 years of experience in the field [1][2] Clinical Programs - Current Programs: - INB-100: Focused on leukemia, specifically acute myeloid leukemia (AML) - INB-200 and INB-400: Genetically modified gamma delta T cell programs targeting solid tumors, with INB-200 focusing on glioblastoma - Clinical Results: - Patients in remission for over 4 years, particularly in severe cases of AML and glioblastoma [2][3] - Pipeline Status: - INB-300 and INB-500 programs are currently on hold due to capital constraints [4] Financials - Recent Financing: - Raised $40.2 million in December, with $20.1 million in the first tranche expected to last until the first half of 2027 [3] - Future Funding: A second tranche is contingent on achieving specific milestones later in the year [3][33] Treatment Approach - Unique Strategy: - Focus on reducing tumor mass to minimal residual disease before attacking remaining cells with gamma delta T cells, which are engineered to survive conventional chemotherapy [8][9] - Dosing Strategy: - Patients receive doses every 28 days, aiming to keep tumor cells static or reduce them over time [10][11] Clinical Data - Patient Outcomes: - Median progression-free survival for control patients was 6.6 months, while those receiving multiple doses had a median progression-free survival of 13 months and overall survival of 17.2 months [16][17] - Statistical Significance: - Data shows a direct correlation between the number of doses and survival rates, with a P value of less than 0.05 indicating statistical significance [20] T-Cell Engager Platform - New Platform: - INB-619 T cell engager platform aims to widen the therapeutic window and improve tolerability in autoimmune diseases [4][21] - Challenges in Autoimmune Treatment: - Current therapies often lead to lymphodepletion and associated risks, particularly for women of childbearing age [21][22] - Innovative Design: - The new T-cell engager targets both CD19 and gamma delta T cells, aiming to avoid common issues like cytokine release syndrome (CRS) [24][25] Competitive Landscape - Market Position: - IN8bio believes it is undervalued compared to competitors, citing its unique approach and promising clinical results [32] - Head-to-Head Comparisons: - Conducted experiments against FDA-approved drugs, demonstrating equivalent or superior B-cell depletion with a wider therapeutic window [27][28] Future Outlook - Regulatory Path: - Plans to seek FDA guidance based on current data, with potential for accelerated approval pathways [34] - Upcoming Milestones: - Anticipated updates on clinical data and animal model results later in the year [32][33] Conclusion - IN8bio is positioned as a leader in gamma delta T cell therapeutics, with promising clinical data and a unique approach to treating difficult cancers and autoimmune diseases. The company is actively seeking to advance its pipeline and regulatory strategy while addressing capital constraints.